Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor

Journal of Clinical Oncology

Volumn 10, Issue 4, 1992, Pages 647-656

  Rowinsky, Eric K ^a   Grochow, Louise B ^a   Hendricks, Carolyn B ^a   Ettinger, David S ^a   Forastiere, Arlene A ^a   Hurowitz, Lisa A ^a   McGuire, William P ^a   Sartorius, Susan E ^a   Lubejko, Barbara G ^a   Kaufmann, Scott H ^a   Donehower, Ross C ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; DRUG ANALOG; GYRASE INHIBITOR; TOPOTECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; BLOOD SAMPLING; CLINICAL ARTICLE; CONFERENCE PAPER; DOSE CALCULATION; DOSE RESPONSE; DRUG DISPOSITION; DRUG EXCRETION; DRUG HALF LIFE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0026537874     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hsiang Y-H, Hertzberg R, Hecht S, et al: Camptothecin induces protein-linked DNA breaks via mamalian DNA topoisomerase I. J Biol Chem 260:14873-14878, 1987
2. Hsiang Y-H, Liu LF: Identification of mamalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988
3. Eng W-K, Faucette L, Johnson RK, et al: Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34:755-760, 1988
4. Jaxel C, Kohn KW, Wani MC, et al: Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49:1465-1469, 1989
5. D'Arpa P, Liu LF: Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 989:163-177, 1989
6. Liu LF: DNA topoisomerase poisons as antitumor agents. Annu Rev Biochem 58:351-375, 1989
7. Kaufmann SH: Additional members of the rat liver lamin polypeptide family. J Biol Chem 264:13946-13955, 1989
8. Hwang J, Shyy S, Chen AY, et al: Studies of topoisomerase-specific anti-tumor drugs in human lymphocytes using rabbit antisera against recombinant human topoisomerase II polypeptide. Cancer Res 49:958-962, 1989
9. Duguet M, Lavenot C, Harper F, et al: DNA topoisomerase from rat liver: Physiological variations. Nucleic Acids Res 11:1059-1075, 1983
10. Liu LF, Miller KG: Eukaryotic DNA topoisomerases. Two forms of type I DNA topoisomerase from HeLa cell nuclei. Proc Natl Acad Sci USA 78:3487-3491, 1981
11. Giovanella BC, Stehlin JS, Wall ME, et al: DNA topoisomerase I target chemotherapy of human colon cancer xenografts. Science 246:1046-1048, 1989
12. Johnson RK, Hertzberg RP, Kingsbury WD, et al: Preclinical profile of SK&F 104864, a water soluble analogue of camptothecin. Proceedings of the Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy, 1989, p 301
13. Kingsbury WD, Boehm JC, Jakas DR, et al: Synthesis of water-soluble (aminoalkyl)camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem 34:98-107, 1991
14. Hertzberg RP, Caranfa MJ, Holden KG, et al: Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32:715-717, 1989
15. Gottlieb JA, Guarino AM, Call JB, et al: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54:461-470, 1970
16. Muggia FM, Creaven PJ, Hansen HH, et al: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother Rep 56:515-521, 1972
17. Moertel CG, Schutt AJ, Reitmeir RJ, et al: Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56:95-101, 1972
18. Gottlieb JA, Luce JK: Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56:103-105, 1972
19. Creaven PJ, Allen LM, Muggia FM: Plasma campotothecin (NSC-100880) levels during a 5-day course of treatment: Relation to dose and toxicity. Cancer Chemother Rep 56:573-578, 1972
20. Underberg WJM, Goosen RMJ, Smith BR, et al: Equilibrium kinetics of the new experimental anti-tumor compound SK&F 104864-A in aqueous solution. J Pharm Biomed Anal 8:681-683, 1990